**ICD-O Update**

**Effective January 1, 2021**

**Table 6: Combined 2021 ICD-O-3.2 update (numerical)**

**Status abbreviations used in the update table**

|  |  |
| --- | --- |
| **Status**  | **Definition** |
| **BC** | Behavior code change (change in reportability) |
| **CC** | Per ICD-O-3.2, several ICD-O codes have been deleted and the histologies moved to other codes.  |
| **NC/T** | New ICD-O code and term |
| **PT** | Preferred term |
| **RT** | Related term |
| **Syn** | Synonym |

Histology terms are per WHO. Preferred terms are indicated in **BOLD** font.

Applicable C codes will be noted next to the term in **BOLD** font.

Coding instructions, if applicable, are noted in the “Comments” column.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Status** | **ICD-O-3.2****Morphology****Code** | **Term(s)** | **Reportable****Y/N** | **Comments** |
| RT | 8020/3 | Anaplastic undifferentiated carcinoma **(C73.9)** | Y |  |
| RT | 8020/3  | Carcinoma, poorly differentiated, NOS | Y |  |
| RT | 8020/3 | Dedifferentiated carcinoma | Y |  |
| RT | 8054/3 | Warty-basaloid carcinoma  | Y |  |
| RT | 8071/3 | Keratoacanthoma | Y |  |
| RT | 8074/3 | Pseudovascular squamous cell carcinoma | Y |  |
| Syn | 8077/2 | High grade squamous intraepithelial lesion | Y |  |
| Syn | 8077/2 | Squamous dysplasia, high grade | Y |  |
| Syn | 8077/2 | Squamous intraepithelial neoplasm, grade II | See comments | The term “squamous intraepithelial neoplasm, grade II” is **NOT** reportable for C53. \_ |
| RT | 8083/3 | Papillary-basaloid carcinoma | Y |  |
| RT | 8090/3 | Basal cell carcinoma with adnexal differentiation (C44. \_)  | N | Not reportable |
| PT | 8091/3 | **Superficial basal cell carcinoma (C44. \_)** | N | Not reportable |
| Syn | 8091/3 | Multifocal superficial basal cell carcinoma **(C44. \_)** | N | Not reportable |
| PTSyn | 8110/3 | **Pilomatrical carcinoma** **(C44. \_)**Pilomatrix carcinoma **(C44. \_)** | NN | Not reportableNot reportable |
| RT  | 8120/3 | Squamotransitional carcinoma | Y |  |
| PT | 8122/3 | **Urothelial carcinoma, sarcomatoid** | Y |  |
| Syn | 8122/3 | Urothelial carcinoma, spindle cell | Y |  |
| Syn | 8122/3 | Transitional cell carcinoma, spindle cell |  |  |
| PT | 8130/1 | **Papillary urothelial neoplasm of low-malignant potential (C67. \_)** | N | Not reportable |
| Syn | 8130/1 | Papillary transitional cell neoplasm of low-malignant potential (C67. \_) | N | Not reportable |
| Syn | 8131/3 | Transitional cell carcinoma, micropapillary | Y |  |
| Syn | 8140/3 | Adenocarcinoma, usual type | Y |  |
| RT | 8140/3 | Acinar adenocarcinoma of prostate (C61.9) | Y |  |
| RT | 8140/3 | Carcinoma of Skene, Cowper and Littre Glands | Y |  |
| RT | 8140/3 | Endolymphatic sac tumor | Y |  |
| RT | 8140/3 | Parathyroid tumor (C75.0) | Y |  |
| BC | 8150/3 | **Pancreatic neuroendocrine tumor, nonfunctioning (C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021. |
| Syn | 8150/3 | Pancreatic endocrine tumor, nonfunctioning **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| Syn | 8150/3 | Pancreatic endocrine tumor, NOS **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8150/3 | Islet cell adenoma **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8150/3 | Islet cell adenomatosis **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8150/3 | Nesidioblastoma **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8150/3 | Islet cell tumor, NOS **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8150/3 | Islet cell adenocarcinoma **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8150/3 | Islet cell carcinoma **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| BC | 8151/3 | **Insulinoma, NOS (C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021. |
| Syn | 8151/3 | Beta cell adenoma **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021. |
| Syn | 8151/3 | Beta cell tumor, malignant **(C25.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021. |
| BC | 8158/3 | **ACTH-producing tumor** | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8158/3 | Endocrine tumor, functioning, NOS | Y | Reportable for cases diagnosed 1/1/2021 forward. **Not reportable** prior to 1/1/2021 |
| RT | 8200/3 | Thymic carcinoma with adenoid cystic carcinoma-like features (C37.9) | Y |  |
| Syn | 8230/3 | Solid adenocarcinoma, NOS | Y |  |
| Syn | 8244/3 | Mixed carcinoid and adenocarcinoma | Y |  |
| Syn | 8246/3 | Poorly differentiated neuroendocrine neoplasm | Y |  |
| PT | 8249/3 | **Neuroendocrine tumor, grade 2** | YYY |  |
| Syn | 8249/3 | Atypical carcinoid tumor | Y |  |
| RT | 8249/3 | Neuroendocrine tumor, grade 3 | Y |  |
| NC/T | 8273/3 | **Pituitary blastoma (C75.1)** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| Syn | 8273/3 | Embryoma | Y | Reportable for cases diagnosed 1/1/2021 forward |
| PT | 8313/1 | **Clear cell borderline tumor (C56.9)** | N | Not reportable |
| Syn | 8313/1 | Clear cell cystic tumor of borderline malignancy **(C56.9)** | N | Not reportable |
| Syn | 8313/1 | Clear cell tumor, atypical proliferation **(C56.9)** | N | Not reportable |
| RT | 8313/1 | Clear cell adenofibroma of borderline malignancy **(C56.9)** | N | Not reportable |
| Syn | 8315/3 | Glycogen-rich clear cell carcinoma | Y |  |
| PT | 8330/3 | **Follicular carcinoma, NOS (C73.9)** | Y |  |
| Syn | 8330/3 | Follicular adenocarcinoma **(C73.9)** | Y |  |
| BC | 8335/1 | **Follicular carcinoma, encapsulated** | N | Cases diagnosed prior to 1/1/2021 are reportable and coded to 8335/3. Cases diagnosed 1/1/2021 and after are not reportable.  |
| PT | 8335/1 | **Follicular tumor of uncertain malignant potential** | N |  |
| PT | 8337/3 | **Poorly differentiated thyroid carcinoma (C73.9)** | Y |  |
| Syn | 8337/3 | Insular carcinoma **(C73.9)** | Y |  |
| PT | 8342/3 | **Papillary carcinoma, oncocytic variant (C73.9)** | Y |  |
| Syn | 8342/3 | Papillary carcinoma, oxyphilic cell **(C73.9)** | Y |  |
| NC/T | 8349/1 | **Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) C73.9)** | N | This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward.  |
| NC/T | 8349/1 | **Non-invasive FTP** | N | This term was previously coded to 8343/2 and was reportable. This term has changed both ICD-O and behavior codes and is no longer reportable for cases diagnosed 1/1/2021 forward |
| BC | 8380/2 | **Endometrioid intraepithelial neoplasia (C54.1)** | Y | Reportable for cases diagnosed 1/1/2021 forward. ***Not reportable*** prior to 1/1/2021 |
| PT | 8390/3 | **Adnexal adenocarcinoma (C44. \_)** | Y |  |
| Syn | 8390/3 | Skin appendage carcinoma **(C44. \_)**  | Y |  |
| PT | 8402/3 | **Hidradenocarcinoma (C44. \_)** | Y |  |
| Syn | 8402/3 | Nodular hidradenoma, malignant **(C44. \_)** | Y |  |
| PT | 8407/3 | **Microcystic adnexal carcinoma (C44. \_)** | Y |  |
| Syn | 8407/3 | Sclerosing sweat duct carcinoma **(C44. \_)** | Y |  |
| PT | 8408/3 | **Digital papillary adenocarcinoma (C44. \_)** | Y |  |
| Syn | 8408/3 | Eccrine papillary adenocarcinoma **(C44. \_)** | Y |  |
| Syn/BC | 8408/3 | Aggressive digital papillary adenoma **(C44. \_)** see comments\* | See comments | The term “*Aggressive digital papillary adenoma*” has changed behavior from /1 to /3. Cases diagnosed prior to 1/1/2021 with this term are not reportable. Cases with this term diagnosed 1/1/2021 and after are reportable |
| PT | 8409/3 | **Porocarcinoma (C44. \_)** | Y |  |
| Syn | 8409/3 | Eccrine poroma, malignant **(C44. \_)** | Y |  |
| PT | 8410/3 | **Sebaceous carcinoma (C44. \_)** | Y |  |
| Syn | 8410/3 | Sebaceous adenocarcinoma **(C44. \_)** | Y |  |
| PT | 8441/3 | **Serous cystadenocarcinoma, NOS (56.9)** | Y | Cases diagnosed prior to 1/1/2021 use code 8460/3 |
| Syn | 8441/3 | Serous papillary adenocarcinoma, NOS **(C56.9)** | Y | Cases diagnosed prior to 1/1/2021 use code 8460/3 |
| Syn | 8441/3 | Papillary serous cystadenocarcinoma **(56.9)** | Y | Cases diagnosed prior to 1/1/2021 use code 8460/3 |
| Syn | 8441/3 | Papillary serous adenocarcinoma **(C56.9)** | Y | Cases diagnosed prior to 1/1/2021 use code 8460/3 |
| Syn | 8441/3 | Serous surface papillary carcinoma **(C56.9)** | Y | Cases diagnosed prior to 1/1/2021 use code 8460/3 |
| PT | 8452/3 | **Solid pseudopapillary neoplasm of the pancreas (C25. \_)** | Y |  |
| RT | 8452/3 | Solid pseudopapillary carcinoma | Y |  |
| BC | 8470/2 | **Mucinous cystic neoplasm with high grade dysplasia (C25. \_)** | Y |  |
| RT | 8470/2 | Mucinous cystadenocarcinoma, non-invasive **(C25. \_)** | Y |  |
| CC | 8470/3 | Papillary mucinous cystadenocarcinoma (C56.9) | Y | Cases diagnosed prior to 1/1/2021 use code 8471/3Cases diagnosed 1/1/2021 forward use code 8470/3 |
| CC | 8470/3 | Papillary pseudomucinous cystadenocarcinoma (C56.9) | Y | Cases diagnosed prior to 1/1/2021 use code 8471/3Cases diagnosed 1/1/2021 forward use code 8470/3 |
| Syn | 8482/3 | Mucinous adenocarcinoma, endocervical type | Y |  |
| RT/BC | 8500/2 | Cystic hypersecretory carcinoma **(C50. \_)**  | Y | Cases diagnosed prior to 1/1/2021, code to 8508/3. ICD-O-3.2 now lists this term under 8500 with a behavior code of 2. |
| RT | 8509/2 | Endocrine mucin-producing sweat gland carcinoma in situ **(C44. \_)**  | Y |  |
| RT | 8509/3 | Endocrine mucin-producing sweat gland carcinoma **(C44. \_)**  | Y |  |
| RT | 8510/3 | Medullary-like carcinoma | Y |  |
| PT | 8580/3 | **Thymoma, NOS (C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8580/3 | Intrapulmonary thymoma **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8580/3 | Sclerosing thymoma **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8580/3 | Metaplastic thymoma **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| PT | 8581/3 | **Thymoma, type A (C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8581/3 | Thymoma, medullary **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8581/3 | Thymoma, spindle cell **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| PT | 8582/3 | **Thymoma, type AB (C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8582/3 | Thymoma, mixed type **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| PT | 8583/3 | **Thymoma, type B1 (C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8583/3 | Thymoma, lymphocyte-rich **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8583/3 | Thymoma, lymphocytic **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8583/3 | Thymoma, organoid **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8583/3 | Thymoma, predominantly cortical **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| PTRT | 8584/3 | **Thymoma, type B2 (C37.9)**Thymoma, cortical **(C37.9)** | YY | “Malignant” removed from pre-ICD-O-3.2 term |
| PT | 8585/3 | **Thymoma, type B3 (C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8585/3 | Thymoma, atypical **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| RT | 8585/3 | Thymoma, epithelial **(C37.9)** | Y | “Malignant” removed from pre-ICD-O-3.2 term |
| PT | 8589/3 | **Intrathyroid thymic carcinoma (C73.9)** | Y |  |
| Syn | 8589/3 | Carcinoma showing thymus-like element | Y |  |
| BC | 8620/3 | **Granulosa cell tumor, adult type (C56.9)** | Y | Granulosa cell tumor, adult type of the ovary diagnosed prior to 1/1/2021 are not reportable. Cases diagnosed 1/1/2021 forward are now reportable.  |
| BC | 8680/3 | **Paraganglioma, NOS (C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| BC | 8682/3 | **Parasympathetic paraganglioma (C75.5)** |  | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| BC | 8690/3 | **Middle ear paraganglioma (C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8690/3 | Glomus jugulare tumor, NOS **(C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8690/3 | Jugular paraganglioma **(C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8690/3 | Jugulotympanic paraganglioma **(C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| BCSynSyn | 8691/3 | **Aortic body tumor (C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8691/3 | Aortic body paraganglioma **(C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8691/3 | Aorticopulmonary paraganglioma **(C75.5)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| BC | 8692/3 | **Carotid body paraganglioma (C75.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8692/3 | Carotid body tumor **(C75.4)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| BC | 8693/3 | **Extra-adrenal paraganglioma, NOS**  | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8693/3 | Nonchromaffin paraganglioma, NOS  | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8693/3 | Laryngeal paraganglioma | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8693/3 | Vagal paraganglioma | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8693/3 | Chemodectoma | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8693/3 | Composite paraganglioma | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| BC | 8700/3 | **Pheochromocytoma, NOS (C74.1)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8700/3 | Adrenal medullary paraganglioma **(C74.1)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8700/3 | Chromaffin paraganglioma | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8700/3 | Chromaffin tumor | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8700/3 | Chromaffinoma | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8700/3 | Composite pheochromocytoma **(C74.1)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8700/3 | Pheochromoblastoma **(C74.1)** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8720/2 | Early/Evolving melanoma in situ **(C44. \_)** | Y | Early/Evolving melanoma in situ is reportable for cases diagnosed 1/1/2021 forward |
| RT | 8720/3 | Nevoid melanoma **(C44. \_)** | Y |  |
| RT | 8720/3 | Melanoma, meningeal **(C70. \_)** | Y |  |
| RT | 8720/3 | Early/Evolving invasive melanoma **(C44. \_)** | Y | “Early/evolving invasive melanoma” is reportable for cases diagnosed 1/1/2021 forward |
| PT | 8743/3 | **Low cumulative sun damaged melanoma (C44. \_)** | Y |  |
| RT | 8743/3 | Superficial spreading melanoma **(C44. \_)** | Y |  |
| PT | 8744/3 | **Acral melanoma (C44. \_)** | Y |  |
| Syn | 8744/3 | Acral lentiginous melanoma, malignant **(C44. \_)** | Y |  |
| PT | 8761/3 | **Malignant melanoma arising in giant congenital nevus (C44. \_)** | Y |  |
| Syn | 8761/3 | Malignant melanoma in giant pigmented nevus **(C44. \_)** | Y |  |
| PT | 8770/3 | **Malignant Spitz tumor (C44. \_)** | Y |  |
| RT | 8770/3 | Mixed epithelioid and spindle cell melanoma | Y |  |
| Syn | 8780/3 | Melanoma arising in a blue nevus **(C44. \_)** | Y |  |
| RT | 8802/3 | Pleomorphic dermal sarcoma **(C44. \_)** | Y |  |
| Syn | 8802/3 | Pleomorphic cell sarcoma, undifferentiated | Y |  |
| Syn | 8802/3 | Pleomorphic sarcoma | Y |  |
| Syn | 8815/3 | Hemangiopericytoma, malignant | Y | Cases diagnosed ***prior*** to 1/1/2021 use code 9150/3Cases diagnosed 1/1/2021 forward use code 8815/3 |
| BC | 8832/1 | Dermatofibrosarcoma protuberans, NOS | N | Cases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable. |
| Syn | 8832/1 | Dermatofibrosarcoma, NOS | N | Cases diagnosed prior to 1/1/2021, report the case and code to 8832/3. Cases diagnosed 1/1/2021 forward are not reportable. |
| Syn | 8832/3 | Dermatofibrosarcoma, sarcomatous **(C44. \_)** | Y |  |
| BCSyn | 8833/1 | Pigmented dermatofibrosarcoma protuberans (C44. \_) | N | Cases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable. |
| Syn | 8833/1 | Bednar tumor (C44. \_) | N | Cases diagnosed prior to 1/1/2021, report the case and code to 8833/3. Cases diagnosed 1/1/2021 forward are not reportable. |
| Syn | 8912/3 | Rhabdomyosarcoma, spindle-cell/sclerosing type | Y |  |
| PT | 8921/3 | **Ectomesenchymoma**  | Y |  |
| Syn | 8921/3 | Rhabdomyosarcoma with ganglionic differentiation | Y |  |
| BC | 8936/3 | **Gastrointestinal stromal tumor** | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8936/3 | GIST, malignant | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8936/3 | Gastrointestinal stromal sarcoma | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8936/3 | Gastrointestinal autonomic nerve tumor | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| Syn | 8936/3 | GANT | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| RT | 8936/3 | Gastrointestinal pacemaker cell tumor | Y | Reportable for cases diagnosed 1/1/2021 forward. Not reportable prior to 1/1/2021 |
| PT | 8963/3 | **Rhabdoid tumor, NOS** | Y |  |
| Syn | 8963/3 | Malignant rhabdoid tumor | Y |  |
| PT | 8982/3 | **Myoepithelial carcinoma** | Y |  |
| Syn | 8982/3 | Malignant myoepithelioma | Y |  |
| BC | 9080/1 | **Immature teratoma of the lung (C34. \_)** | N | Immature teratomas arising in lung are not reportable for cases diagnosed 1/1/2021 forward. |
| BC | 9080/1 | **Immature teratoma of the thymus (C37.9)** | N | Immature teratomas arising in thymus are not reportable for cases diagnosed 1/1/2021 forward. |
| BC | 9080/1 | **Immature teratoma of the thyroid (C73.9)** | N | Immature teratomas arising in thyroid are not reportable for cases diagnosed 1/1/2021 forward. |
| PT | 9310/3 | **Ameloblastoma, metastasizing** | Y |  |
| Syn | 9310/3 | Ameloblastoma, malignant | Y |  |
| PT | 9364/3 | **Ewing sarcoma** | Y | 1/1/2021 forward Ewing sarcoma is the preferred term for 9364/3 and is no longer coded to 9260/3. Cases diagnosed prior to 1/1/2021 should be coded to 9260/3.  |
| PT | 9391/3 | **Sellar ependymoma (C75.1)** | Y |  |
| Syn | 9411/3 | Gemistrocytic astrocytoma IDH mutant **(C71. \_)** | Y |  |
| PT | 9473/3 | **CNS Embryonal tumor, NOS**  | Y |  |
| RT | 9475/3 | Medulloblastoma, WNT-activated, classic **(C71.6)** | Y |  |
| RT | 9475/3 | Medulloblastoma, WNT-activated, large cell type **(C71.6)** | Y |  |
| RT | 9475/3 | Medulloblastoma, WNT-activated, anaplastic type **(C71.6)** | Y |  |
| RT | 9477/3 | Medulloblastoma, group 3 **(C71.6)** | Y |  |
| RT | 9477/3 | Medulloblastoma, group 4 **(C71.6)** | Y |  |
| BC | 9505/0 | **Multinodular and vascolating neuronal tumor (MVNT) (C71.2)** | Y | WHO has not yet assigned a specific ICD-O code for this neoplasm. In the interest of collecting these tumors, 9505/0 has been assigned by neuropathology experts. |
| Removed from ICD-O-3.2 | 9540/1 | Neurofibromatosis, NOS | N | WHO has removed neurofibromatosis from ICD-O-3.2. This disease is not reportable for cases diagnosed 1/1/2018 forward per Solid Tumor Rules |
| NC/T | 9673/1 | In situ mantle cell neoplasm | N | Not reportable |
| Syn | 9673/1 | In situ mantle cell lymphoma | N | Not reportable |
| PT | 9680/3 | **Diffuse large B-cell lymphoma, NOS** | Y |  |
| Syn | 9680/3 | Malignant lymphoma, large B-cell, diffuse, NOS | Y |  |
| RT | 9680/3 | Diffuse large B-cell lymphoma, germinal center B-cell subtype | Y |  |
| RT | 9680/3 | Diffuse large B-cell lymphoma, activated B-cell subtype | Y |  |
| RT | 9680/3 | Vitreoretinal lymphoma **(C69. \_)** | Y |  |
| CC | 9687/3 | Burkitt cell leukemia (see also M-9687/3) | Y | Cases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3 |
| CC | 9687/3 | Acute leukemia, Burkitt type [obs] | Y | Cases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3 |
| CC | 9687/3 | Acute lymphoblastic leukemia, mature B-cell type | Y | Cases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3 |
| CC | 9687/3 | B-ALL [obs] | Y | Cases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3 |
| CC | 9687/3 | FAB L3 [obs] | Y | Cases diagnosed prior to 1/1/2021 use code 9826/3Cases diagnosed 1/1/2021 forward use code 9687/3 |
| RT | 9690/3 | Follicular lymphoma, pediatric type | Y |  |
| NC | 9695/1 | In situ follicular neoplasm | N | In situ lymphoma is not reportable |
| Syn | 9685/1 | In situ follicular lymphoma | N | In situ lymphoma is not reportable |
| RT | 9695/3 | Follicular lymphoma, duodenal type **(C17.0)** | Y |  |
| RT | 9698/3 | Large B-cell lymphoma with IRF4 rearrangement | Y |  |
| RT | 9699/3 | Primary choroidal lymphoma (C69.3) | Y |  |
| Syn | 9699/3 | Bronchus associated lymphoid tissue lymphoma | Y |  |
| Syn | 9699/3 | Mucosa associated lymphoid tissue lymphoma | Y |  |
| BC | 9709/1 | Primary cutaneous CD4-positive small/medium T-cell lymphoma (C44. \_) | N | Cases diagnosed prior to 1/1/2021, report the case and code to 9709/3. Cases diagnosed 1/1/2021 forward are not reportable |
| NC/T | 9715/3 | **Anaplastic large cell lymphoma, ALK negative** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| RT | 9715/3 | Breast implant-associated anaplastic large cell lymphoma (C50. \_) | Y | Reportable for cases diagnosed 1/1/2021 forward |
| BC | 9718/1 | Primary cutaneous CD30+ T cell lymphoproliferative disorder (C44. \_) | N | Cases diagnosed prior to 1/1/2021, report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportable |
| BC | 9718/1 | Lymphoid papulosis (C44. \_) | N | Cases diagnosed prior to 1/1/2021, report the case and code to 9718/3. Cases diagnosed 1/1/2021 forward are not reportable |
| BC | 9725/1 | Hydroa vacciniforme-like lymphoproliferative disorder | N | Cases diagnosed prior to 1/1/2021, report the case and code to 9725/3. Cases diagnosed 1/1/2021 forward are not reportable |
| PT | 9732/3 | **Plasma cell myeloma (C42.1)** | Y |  |
| Syn | 9732/3 | Multiple myeloma **(C42.1)** | Y |  |
| PT | 9738/3 | **HHV8-positive diffuse B-cell lymphoma** | Y |  |
| Syn | 9738/3 | Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease | Y |  |
| NC/T | 9749/3 | **Erdhiem-Chester Disease**  | Y | Reportable for cases diagnosed 1/1/2021 forward |
| BC | 9751/1 | Langerhans cell histiocytosis, NOSLangerhans cell histiocytosis, monostoticLangerhans cell histiocytosis, polystotic | NNN | **Please note, these terms are not reportable. Refer to Hematopoietic Database for reportable terms.** Cases diagnosed prior to 1/1/2021, report the case and code to 9751/3. Cases diagnosed 1/1/2021 forward are not reportable |
| BC | 9766/3 | **Lymphomatoid granulomatosis, grade 3** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| CC | 9811/3 | Precursor B-cell lymphoblastic lymphoma (*see also M-9836/3*) | Y | Cases diagnosed prior to 1/1/2021 use code 9728/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| CC | 9811/3 | Precursor B-cell lymphoblastic leukemia (see also M-9728/3) | Y | Cases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| CC | 9811/3 | c-ALL | Y | Cases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| CC | 9811/3 | Common ALL | Y | Cases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| CC | 9811/3 | Common precursor B ALL | Y | Cases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| CC | 9811/3 | Pre-B ALL | Y | Cases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| CC | 9811/3 | Pre-pre-B ALL | Y | Cases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| CC | 9811/3 | Pro-B ALL | Y | Cases diagnosed prior to 1/1/2021 use code 9836/3Cases diagnosed 1/1/2021 forward use code 9811/3 |
| NC/T | 9819/3 | **B-lymphocytic leukemia/lymphoma, BCR-ABL1-like** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| CC | 9823/3 | Malignant lymphoma, small B lymphocytic, NOS (see also M-9823/3) | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9823/3 | Malignant lymphoma, lymphocytic, diffuse, NOS | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9823/3 | Malignant lymphoma, lymphocytic, NOS | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9823/3 | Malignant lymphoma, lymphocytic, well differentiated, diffuse | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9823/3 | Malignant lymphoma, small cell diffuse | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9823/3 | Malignant lymphoma, small cell, NOS | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9823/3 | Malignant lymphoma, small lymphocytic, diffuse | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9823/3 | Malignant lymphoma, small lymphocytic, NOS | Y | Cases diagnosed prior to 1/1/2021 use code 9670/3Cases diagnosed 1/1/2021 forward use code 9823/3 |
| CC | 9837/3 | Precursor T-cell lymphoblastic lymphoma (see also M-9837/3) | Y | Cases diagnosed prior to 1/1/2021 use code 9729/3Cases diagnosed 1/1/2021 forward use code 9837/3 |
| PT | 9840/3 | **Acute erythroid leukemia** | Y |  |
| Syn | 9840/3 | Acute myeloid leukemia, M6 type | Y |  |
| NC/T | 9877/3 | **Acute myeloid leukemia with mutated NPM1** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| NC/T | 9878/3 | **Acute myeloid leukemia with biallelic mutations of CEBPA** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| NC/T | 9879/3 | **Acute myeloid leukemia with mutated RUNX1** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| NC/T | 9912/3 | **Acute myeloid leukemia with BCR-ABL1** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| NC/T | 9968/3 | **Myeloid/lymphoid neoplasm with PCM1-JAK2** | Y | Reportable for cases diagnosed 1/1/2021 forward |
| BC | 9971/1 | Post-transplant lymphoproliferative disorder, NOS | N | Cases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportable |
| BC | 9971/3 | PTLD, NOS | N | Cases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportable |
| BC | 9971/3 | Polymorphic post-transplant lymphoproliferative disorder | N | Cases diagnosed prior to 1/1/2021, report the case and code to 9971/3. Cases diagnosed 1/1/2021 forward are not reportable |
| PT | 9980/3 | **Myelodysplastic syndrome with single lineage dysplasia** | Y |  |
| Syn | 9980/3 | Refractory anemia |  |  |
| CC | 9980/3 | Refractory neutropenia | Y | Cases diagnosed prior to 1/1/2021 use code 9991/3Cases diagnosed 1/1/2021 forward use code 9980/3 |
| CC | 9980/3 | Refractory thrombocytopenia  | Y | Cases diagnosed prior to 1/1/2021 use code 9992/3 Cases diagnosed 1/1/2021 forward use code 9980/3 |
| PT | 9982/3 | **Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia** | Y |  |
| Syn | 9982/3 | Refractory anemia with excess blasts, NOS | Y |  |
| PT | 9985/3 | **Myelodysplastic syndrome with multilineage dysplasia** | Y |  |
| Syn | 9985/3 | Refractory cytopenia with multilineage dysplasia | Y |  |
| RT | 9985/3 | Refractory cytopenia of childhood | Y |  |
| PT | 9986/3 | **Myelodysplastic syndrome with isolated del (5q)** | Y |  |
| Syn | 9986/3 | Myelodysplastic syndrome with 5q deletion (5q-) syndrome | Y |  |
| PT | 9993/3 | **Myelodysplastic syndrome with ring sider0blasts and multilineage dysplasia**  | Y |  |